The study, entitled COMET (Comparison of Operative to
Medical Endocrine Therapy) for low - risk ductal carcinoma in situ, received funding through a $ 13.4 million, five - year award from the Patient - Centered Outcomes Research Institute (PCORI), an independent, nonprofit organization authorized by Congress in 2010 to support research that enlightens health care decisions.
Not exact matches
Kent Holtorf, M.D., the developer of Holtraceuticals, is the founder of the Holtorf
Medical Group, which specializes in integrative and natural
therapies, endocrinology, thyroid dysfunction, fatigue syndromes, adrenal insufficiency, chronic fatigue syndrome, fibromyalgia, chronic infections and complex
endocrine dysfunction.
It can be used alongside other
medical therapies to treat a wide variety of ailments including; pain relief from musculoskeletal problems such as arthritis, neurological disorders like seizures, diarrhea and constipation, behavioral issues,
endocrine disorders and other chronic conditions.